Local tissue factor pathway inhibitor release in the human forearm

Thrombosis and Haemostasis

Volumn 89, Issue 3, 2003, Pages 438-445

  Kemme, Michiel J B ^a   Burggraaf, Jacobus ^a   Schoemaker, Rik C ^a   Cohen, Adam F ^a   Kluft, Cornelis ^b   Chia, Stanley ^c   Webb, David J ^c   Newby, David E ^c  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b TNO   (Netherlands)

^c UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Bradykinin; Haemostasis; Heparin; Substance P; Tissue factor pathway inhibitor

Indexed keywords

BRADYKININ; HEPARIN; NITROPRUSSIDE SODIUM; PLACEBO; PROTHROMBIN; SODIUM CHLORIDE; SUBSTANCE P; TISSUE FACTOR PATHWAY INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VASODILATOR AGENT;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; BRACHIAL ARTERY; CONTROLLED STUDY; DOSE RESPONSE; DRUG INFUSION; DRUG SENSITIVITY; ENDOTHELIUM; FOREARM; FOREARM BLOOD FLOW; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; STUDENT T TEST; SYSTEMIC CIRCULATION;

EID: 0037342031     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1613371     Document Type: Article

References (34)

1. Kato H. Regulation of functions of vascular wall cells by tissue factor pathway inhibitor: Basic and clinical aspects. Arterioscler Thromb Vasc Biol 2002; 22: 539-48.
2. Crawley J, et al. Expression, localization, and activity of tissue factor pathway inhibitor in normal and atherosclerotic human vessels. Arterioscler Thromb Vasc Biol 2000; 20: 1362-73.
3. Broze GJ, Jr., et al. Heterogeneity of plasma tissue factor pathway inhibitor. Blood Coagul Fibrinolysis 1994; 5: 551-9.
4. Soejima H, et al. Hightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina. Circulation 1999; 99: 2908-2913
5. Taubman MB, et al. Tissue factor in the pathogenesis of atherosclerosis. Thromb Haemost 1997; 78: 200-4.
6. Wilcox JN, et al. Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. Proc Natl Acad Sci USA 1989; 86: 2839-43.
7. Abendschein DR, et al. Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 1995; 92: 944-9.
8. Abraham E. Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. Crit Care Med 2000; 28: S31-S33.
9. Rao AK, et al. Activation of the tissue factor pathway of blood coagulation during prolonged hyperglycemia in young healthy men. Diabetes 1999; 48: 1156-61.
10. Idell S. Extravascular coagulation and fibrin deposition in acute lung injury. New Horiz 1994; 2: 566-74.
11. Tipping PG, et al. Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol 1995; 147: 1736-48.
12. Sakkinen PA, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998; 80: 134-9.
13. Bajaj MS, Bajaj SP. Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 1997; 78: 471-477
14. Kojima T, et al. Another point of view on the mechanism of thrombin generation during cardiopulmonary bypass: Role of tissue factor pathway inhibitor. J Cardiothorac Vasc Anesth 2001; 15: 60-4.
15. Badimon JJ, et al. Local inhibition of tissue factor reduces the thrombogenicity of disrupted human atherosclerotic plaques: Effects of tissue factor pathway inhibitor on plaque thrombogenicity under flow conditions. Circulation 1999; 99: 1780-7.
16. Roque M, et al. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty. J Am Coll Cardiol 2000; 36: 2303-10.
17. Carr C, et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 1994; 44: 126-37.
18. Westmuckett AD, et al. Fluid flow induces upregulation of synthesis and release of tissue factor pathway inhibitor in vitro. Arterioscler Thromb Vasc Biol 2000; 20: 2474-82.
19. Grabowski EF, et al. Shear stress decreases endothelial cell tissue factor activity by augmenting secretion of tissue factor pathway inhibitor. Arterioscler Thromb Vasc Biol 2001; 21: 157-62.
20. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). Thromb Res 1988; 50: 803-13.
21. Giraux JL, Tapon-Bretaudiere J, Matou S, Fischer AM. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells. Thromb Haemost 1998; 80: 692-5.
22. Kemme MJ, Burggraaf J, Schoemaker RC, et al. The influence of reduced liver blood flow on the pharmacokinetics and pharmacodynamics of recombinant tissue factor pathway inhibitor. Clin Pharmacol Ther 2000; 67: 504-11.
23. Webb DJ. The pharmacology of human blood vessels in vivo. J Vasc Res 1995;32:2-15.
24. Newby DE, et al. An in vivo model for the assessment of acute fibrinolytic capacity of the endothelium. Thromb Haemost 1997; 78: 1242-8.
25. Alban S, Gastpar R. Plasma levels of total and free tissue factor pathway inhibitor (TFPI) as individual pharmacological parameters of various heparins. Thromb Haemost 2001; 85: 824-9.
26. Labinjoh C, et al. Potentiation of bradykinin-induced tissue plasminogen activator release by angiotensin-converting enzyme inhibition. J Am Coll Cardiol 2001; 38: 1402-8.
27. Labinjoh C, et al. Fibrinolytic actions of intra-arterial angiotensin II and bradykinin in vivo in man. Cardiovasc Res 2000; 47: 707-14.
28. Kemme MJ, et al. Quantification of heparin induced TFPI release: A maximum release at low heparin dose. Br J Clin Pharmacol 2002; 54: 627-34.
29. Stein CM et al. Regulation of local tissue-type plasminogen activator release by endothelium-dependent and endothelium-independent agonists in human vasculature. J Am Coll Cardiol 1998; 32: 117-22.
30. Nilius B, Droogmans G. Ion channels and their functional role in vascular endothelium. Physiol Rev 2001; 81: 1415-59
31. De Boer A, et al. Influence of heparin and a low molecular weight heparinoid on specific endogenous and exogenous fibrinolytic factors during rest and exercise. Thromb Haemost 1992; 68: 550-5.
32. Piatti PM et al. Effects of low-dose heparin infusion on arterial endothelin-1 release in humans. Circulation 1999; 66: 232-8.
33. Tangpao O, et al.. Heparin-induced vasodilation in human hand veins. Clin Pharmacol Ther 1999; 66: 232-8.
34. Yokokawa K, Tahara H, Kohno M, et al. Heparin regulates endothelin production through endothelium-derived nitric oxide in human endothelial cells. J Clin Invest 1993; 92: 2080-5.